Return to homepagePandemic Pact

Clinical utility of the analysis of IL-6 signaling as an indicator of COVID-19 disease activity. Therapeutic opportunity with IL-6 trans-signaling blockers

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00792

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Matilde Bustos de Abajo

  • Research Location

    Spain

  • Lead Research Institution

    Agencia Estatal Consejo Superior de Investigaciones Científicas.

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

1) Analysis of the inflammatory response by means of serum cytokines profile related to IL-6 signaling to stratify patients, assess COVID-19 disease activity and select patients to attenuate the inflammatory response by blocking IL-6. 2) Analysis of SNPs of the genes that participate in IL-6 signaling that can explain exacerbated reactions (bioinformatics data and data to be obtained with our samples). 3) To demonstrate the importance of a selective blockade of IL-6, that is to say to block only the transsignaling of IL-6 in patients where there is a severe inflammatory response with high levels of soluble IL-6 receptor. (sIL-6R) and low sgp130 (natural trans-signaling buffer), does not affect the classic IL-6. This contrasts with the use of Tociluzimab, where all IL-6 responses are inhibited, affecting the classic regenerative and defense IL-6 signaling in inflammation processes.